Type 1 Diabetes

Metabolic Diseases
21
Pipeline Programs
17
Companies
50
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
7
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
563%
Peptide
225%
Vaccine
113%
+ 38 programs with unclassified modality

On Market (4)

Approved therapies currently available

Sanofi
APIDRAApproved
insulin glulisine
Sanofi
Insulin Analog [EPC]intravenous, subcutaneous2004
U
CANDESARTAN CILEXETILApproved
candesartan cilexetil
Unknown Company
oral2017
Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
10 programs
1
3
LiraglutidePhase 4Peptide1 trial
RosiglitazonePhase 41 trial
insulin levemir / aspartPhase 41 trial
LiraglutidePhase 3Peptide1 trial
Closed-loop controlN/A1 trial
+5 more programs
Active Trials
NCT01444443Completed12Est. Jun 2012
NCT06143267Completed10Est. Sep 2024
NCT01223560Completed12Est. May 2010
+7 more trials
Sanofi
SanofiPARIS, France
5 programs
1
1
iBGStar meterPhase 41 trial
SAR342434Phase 11 trial
APIDRA(Insulin)N/A5 trials
Investigational ProcedureN/A1 trial
TZIELDN/A1 trial
Active Trials
NCT05684341Completed200Est. Jun 2024
NCT04678661Terminated60Est. Feb 2023
NCT03903016Completed90Est. Aug 2019
+6 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
2
candesartanPhase 3Small Molecule
candesartan cilexetilPhase 3
Pramlintide acetatePhase 15 trials
Active Trials
NCT02500979Completed34Est. Aug 2016
NCT01708044Completed32Est. Sep 2013
NCT00673387Completed636Est. Oct 2009
+2 more trials
VP
2 programs
1
1
Biological/VaccinePhase 3Vaccine1 trial
VX-264Phase 1/21 trial
Active Trials
NCT05791201Active Not Recruiting7Est. May 2026
NCT06832410Recruiting10Est. Sep 2027
Takeda
TakedaTOKYO, Japan
2 programs
2
candesartanPhase 3Small Molecule1 trial
candesartan cilexetilPhase 31 trial
Active Trials
NCT00252720Completed1,850Est. Apr 2008
NCT00252733Completed5,238Est. Apr 2008
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Dimethyl Fumarate Enteric-coated CapsulesPhase 31 trial
Active Trials
NCT07258394RecruitingEst. Dec 2028
M&
Merck & Co.RAHWAY, NJ
2 programs
1
enalaprilPhase 2Small Molecule1 trial
SitagliptinN/ASmall Molecule5 trials
Active Trials
NCT02683187Completed40Est. Mar 2018
NCT02791490Completed458Est. Feb 2018
NCT02738879Completed746Est. Jan 2018
+3 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Allogeneic islets of Langerhans transplantPhase 1/21 trial
Active Trials
NCT00285233Completed8Est. Mar 2005
Opko Health
Opko HealthMIAMI, FL
1 program
1
E1 and G1Phase 11 trial
Active Trials
NCT00239148CompletedEst. Dec 2006
Insulet
InsuletACTON, MA
5 programs
Insulet Artificial PancreasN/A1 trial
Omnipod 5N/A1 trial
Omnipod 5N/A
Omnipod 5 SystemN/A1 trial
Omnipod Horizon™ Automated Glucose Control SystemN/A1 trial
Active Trials
NCT02897557CompletedEst. Mar 2017
NCT06144554RecruitingEst. Sep 2027
NCT05409131CompletedEst. Jan 2025
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
4 programs
Meal-Tagging App and Web-based Portal:N/A1 trial
Mind-body skillsN/A1 trial
MiniMed 780G SystemN/A1 trial
t:slim X2 insulin pump with Control-IQ technology 1.5N/A1 trial
Active Trials
NCT04667182Withdrawn0Est. Dec 2021
NCT05577169Completed30Est. Dec 2024
NCT05325294Completed244Est. Jan 2024
+1 more trials
Abbott
AbbottABBOTT PARK, IL
3 programs
Different insulin therapy at different time pointsN/A1 trial
Libre Flash CGMSN/A1 trial
No treatmentN/A2 trials
Active Trials
NCT00970567Completed19Est. Dec 2008
NCT02776007Completed60Est. Apr 2020
NCT02073058Completed75Est. May 2014
+1 more trials
Beta Bionics
Beta BionicsIRVINE, CA
2 programs
GlucoSTATN/ASmall Molecule1 trial
iLet Dosing Decision SoftwareN/A1 trial
Active Trials
NCT04227626Withdrawn0Est. Apr 2021
NCT06891898Recruiting1,875Est. Jun 2027
UNEEG Medical
UNEEG MedicalDenmark - Allerod
2 programs
Hyposafe Hypoglycaemia alarm deviceN/A1 trial
Hyposafe hypoglycaemia notification deviceN/A1 trial
Active Trials
NCT01178476Withdrawn0Est. Mar 2011
NCT05495386Withdrawn0Est. Mar 2024
Pfizer
PfizerNEW YORK, NY
1 program
Intensive treatmentN/A1 trial
Active Trials
NCT00444899Completed101Est. Dec 2018
Verona Pharma
Verona PharmaUK - London
1 program
Use of Predictive Alarm for hypoglycaemia or hyperglycaemiaN/A1 trial
Active Trials
NCT05574023Completed20Est. Jun 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
blood drawN/A1 trial
Active Trials
NCT05899439RecruitingEst. Jan 2085

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
SanofiInsulin
SanofiInsulin
SanofiInsulin
SanofiInsulin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
SanofiInsulin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
Merck & Co.Sitagliptin
SanofiInsulin

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 13,309 patients across 50 trials

Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes

Start: Oct 2017Est. completion: Aug 2018375 patients
Phase 4Completed

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Start: Feb 2017Est. completion: Aug 2017184 patients
Phase 4Completed

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

Start: Sep 2016Est. completion: Apr 201914 patients
Phase 4Completed

Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)

Start: May 2016Est. completion: Mar 201718 patients
Phase 4Unknown

Sitagliptin and Glucagon Counterregulation

Start: Apr 2015Est. completion: Jun 201728 patients
Phase 4Completed

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Start: Feb 2015Est. completion: Dec 201553 patients
Phase 4Completed

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM

Start: Jan 2015Est. completion: Jul 201730 patients
Phase 4Unknown

TOFO Insulin Combination Trial

Start: Jun 2014Est. completion: Oct 2016211 patients
Phase 4Completed

Sitagliptin and Brown Adipose Tissue

Start: Mar 2014Est. completion: Dec 201630 patients
Phase 4Completed

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

Start: Jan 2014Est. completion: Jan 20151 patients
Phase 4Terminated

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Start: Sep 2013Est. completion: Sep 201736 patients
Phase 4Completed

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

Start: Sep 2013Est. completion: Oct 202061 patients
Phase 4Completed

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Start: Aug 2013Est. completion: Apr 2016292 patients
Phase 4Completed

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

Start: Jun 2013Est. completion: Jul 201638 patients
Phase 4Completed

Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)

Start: Jun 2013Est. completion: Feb 201472 patients
Phase 4Terminated

52 Week Trial of Liraglutide in Type 1 Diabetes

Start: Apr 2013Est. completion: Apr 201515 patients
Phase 4Completed
NCT01825382SanofiiBGStar meter

Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study

Start: Dec 2012Est. completion: Nov 2013100 patients
Phase 4Completed

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Start: Nov 2012Est. completion: Apr 20155,570 patients
Phase 4Completed

Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

Start: Dec 2011Est. completion: Jul 201524 patients
Phase 4Completed

Simplified Insulin Protocol Using Lantus in Elderly

Start: Jun 2011Est. completion: Sep 201565 patients
Phase 4Completed

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Start: Jan 2011Est. completion: Dec 201249 patients
Phase 4Completed

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial

Start: Jan 2011Est. completion: May 201145 patients
Phase 4Unknown

Performance Evaluation of Blood Glucose Monitoring Systems

Start: Jan 2011Est. completion: Jun 2011106 patients
Phase 4Completed

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Start: Aug 2010Est. completion: Aug 201272 patients
Phase 4Completed

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Start: Jun 2010Est. completion: Nov 20101,147 patients
Phase 4Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Start: May 2010Est. completion: Oct 2013292 patients
Phase 4Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

Start: Jan 2010Est. completion: Jun 2012375 patients
Phase 4Completed

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Start: Jan 2009Est. completion: Jun 2011114 patients
Phase 4Completed

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Start: Dec 2008Est. completion: Mar 201120 patients
Phase 4Completed

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Start: Nov 2008Est. completion: Sep 200910 patients
Phase 4Terminated

Bone Turnover in Type 2 Diabetes Patients

Start: Aug 2008Est. completion: Aug 201020 patients
Phase 4Unknown

ALPHA Sitagliptin Add on to Metformin (0431-103)

Start: Mar 2008Est. completion: Oct 2009608 patients
Phase 4Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

Start: Jan 2008Est. completion: Jun 2009289 patients
Phase 4Completed

Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus

Start: Jul 2007Est. completion: May 2008188 patients
Phase 4Completed
NCT00346996Novo Nordiskinsulin levemir / aspart

Insulin Analogues and Severe Hypoglycaemia

Start: May 2007Est. completion: Aug 2012179 patients
Phase 4Completed
NCT00467649AstraZenecaPramlintide acetate

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Start: May 2007Est. completion: Apr 2008112 patients
Phase 4Completed

Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy

Start: Apr 2007Est. completion: Dec 2012112 patients
Phase 4Completed

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Start: Feb 2007Est. completion: Jul 200829 patients
Phase 4Completed
NCT00240253AstraZenecaPramlintide acetate

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Start: Oct 2005Est. completion: Jun 2006200 patients
Phase 4Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Start: Sep 2005Est. completion: Jun 2006130 patients
Phase 4Completed

APIDRA Registration Study

Start: Aug 200545 patients
Phase 4Completed

Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings

Start: Feb 2005Est. completion: Aug 200650 patients
Phase 4Completed

Rosiglitazone and Insulin in T1DM Adolescents

Start: Aug 2003Est. completion: Sep 200532 patients
Phase 4Completed
NCT07258394Qilu PharmaceuticalDimethyl Fumarate Enteric-coated Capsules

Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

Start: Jan 2026Est. completion: Dec 2028
Phase 3Recruiting

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Start: Mar 2025Est. completion: Sep 202710 patients
Phase 3Recruiting

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Start: Nov 2018Est. completion: Jan 2021370 patients
Phase 3Terminated

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Start: Jun 2016Est. completion: Feb 2018458 patients
Phase 3Completed

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Start: May 2016Est. completion: Jan 2018746 patients
Phase 3Completed

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Start: Nov 2015Est. completion: Nov 2016143 patients
Phase 3Completed

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Start: Nov 2015Est. completion: Nov 2016141 patients
Phase 3Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 13,309 patients
17 companies competing in this space